Analog chipmaker Texas Instruments forecasts quarterly revenue above estimates-June 2024-www.financetom.com

Analog chipmaker Texas Instruments forecasts quarterly revenue above estimates

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Analog chipmaker Texas Instruments forecasts quarterly revenue above estimates

Apr 23, 2024 1:23 PM

April 23 (Reuters) - Chipmaker Texas Instruments

forecast second-quarter revenue above Wall Street estimates on

Tuesday, as consumer electronics demand improved after months of

declines, more than offsetting the impact from chip inventory

corrections in the automotive market.

The Dallas, Texas-based company expects revenue with a

midpoint of $3.8 billion for the quarter, compared with

analysts' average estimate of $3.77 billion, according to LSEG

data.

Previous page： NFI Group Appoints Rob Marion as President of Motor Coach Industries Next page： Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

NFI Group Appoints Rob Marion as President of Motor Coach Industries

Apr 2, 2026

03:55 PM EDT, 04/02/2026 (MT Newswires) -- NFI Group ( NFYEF ) on said Rob Marion will serve as president of the company's Motor Coach Industries (MCI) unit. The bus and coach manufacturer said Marion will start his new role immediately, reporting directly to NFI's chief executive, John Sapp. NFI's former CEO, Paul Soubry, had served as interim president of...

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Apr 2, 2026

– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth – ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Esperion (the Company) today announced the closing of its acquisition of Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for...

Cresco Labs Secures Conditional Texas Medical Cannabis License

Apr 2, 2026

03:57 PM EDT, 04/02/2026 (MT Newswires) -- Cresco Labs ( CRLBF ) said Thursday afternoon it was conditionally awarded a license under the Texas Compassionate Use Program, allowing it to cultivate, process, and dispense medical cannabis. The company said the license supports its state-by-state expansion strategy, with Texas being one of the largest markets in the United States. Winning a...

BRIEF-Spacex Targets More Than $2 Trillion Valuation In IPO - Bloomberg News

Apr 2, 2026

April 2 (Reuters) - * SPACEX TARGETS MORE THAN $2 TRILLION VALUATION IN IPO - BLOOMBERG NEWS Source text: https://tinyurl.com/24kuseh2 ...